Baseline | Post | X difference (95 % CI) | pa | ESa | ||
---|---|---|---|---|---|---|
X ± SD | X ± SD | |||||
SP [mm] | Placebo injured | 1073.9 ± 266.5 | 1033.1 ± 289.2 | -40.8 (1.45 to 2.56) | 0.060 | 0.14 |
Placebo healthy | 967.3 ± 219.77 | 934.8 ± 285.1 | -32.5 (1.24 to 1.64) | 0.104 | 0.12 | |
pb | 0.049 | 0.045 | ||||
ESb | 0.43 | 0.34 | ||||
SPAP [mm] | Placebo injured | 702.4 ± 219.3 | 698.1 ± 217.5 | -4.3 (1.01 to 3.01) | 0.067 | 0.01 |
Placebo healthy | 625.8 ± 234.1 | 616.9 ± 237.6 | -8.9 (1.32 to 1.84) | 0.269 | 0.03 | |
pb | 0.027 | 0.018 | ||||
ESb | 0.33 | 0.35 | ||||
SPML [mm] | Placebo injured | 752.1 ± 208.6 | 728.6 ± 194.8 | -63.5 (1.26 to 2.69) | 0.221 | 0.11 |
Placebo healthy | 690.4 ± 276.3 | 683.9 ± 230.2 | -6,5 (1.23 to 1.54) | 0.138 | 0.02 | |
pb | 0.038 | 0.011 | ||||
ESb | 0.25 | 0.23 | ||||
MV [mm/s] | Placebo injured | 37.3 ± 9.9 | 35.6 ± 9.5 | -1.7 (1.11 to 2.34) | 0.089 | 0.17 |
Placebo healthy | 32.4 ± 5.6 | 31.8 ± 4.7 | -0.6 (0.97 to 2.45) | 0.076 | 0.11 | |
pb | 0.043 | 0.047 | ||||
ESb | 0.60 | 0.50 | ||||
MVAP [mm/s] | Placebo injured | 23.8 ± 7.4 | 22.2 ± 7.9 | -1.6 (1.22 to 2.62) | 0.079 | 0.20 |
Placebo healthy | 19.5 ± 5.9 | 18.9 ± 3.8 | -0.6 (0.21 to 1.31) | 0.139 | 0.12 | |
pb | 0.039 | 0.042 | ||||
ESb | 0.64 | 0.53 | ||||
MVML [mm/s] | Placebo injured | 25.1 ± 6.4 | 23.1 ± 6.2 | -2 (1.29 to 2.97) | 0.112 | 0.31 |
Placebo healthy | 19.9 ± 3.9 | 19.5 ± 4.6 | -0.4 (0.34 to 2.49) | 0.177 | 0.10 | |
pb | 0.047 | 0.034 | ||||
ESb | 0.98 | 0.69 |